Merck, 05-840, Anti-IDO (Indoleamine 2,3-Dioxygenase) Antibody, clone 10.1

General description
Indoleamine 2,3-dioxygenase (IDO) is an enzyme that is responsible for converting tryptophan to kynurenines. IDO is expressed by a wide variety of tissues and IDO can be upregulated by interferon gamma. IDO modulates levels of the amino acid tryptophan, which is vital for cell growth, but is also involved in the suppression of the immune response. IDO may be involved in the suppression of the immune response to tumours and blocking the IDO pathway may be a potential target for immunotherapy.
42 kDa
Immunogen
GST fusion protein corresponding to residues 78-184 of human Indoleamine 2,3- Dioxygenase (IDO). Clone 10.1.
Application
Anti-IDO (Indoleamine 2, 3-Dioxygenase) Antibody, clone 10.1 is an antibody against IDO (Indoleamine 2 for use in IC & WB.
Immunocytochemistry: A previous lot was used by an independent laboratory in Phoenix cells transfected with an expression vector.

Immunohistochemistry: A previous lot of this antibody was used to detect IDO in human retina, primary eye tumor and metastatic liver tumor tissue sections (Chen, P.W., et al. Experimental Eye Research 85(2007) 617-625).
Biochem/physiol Actions
Recognizes IDO (Indoleamine 2,3- Dioxygenase), Mr 42 kDa.
Physical form
Format: Purified
Purified mouse monoclonal IgG in buffer containing 70% storage buffer 0.1 M Tris-glycine, pH 7.4, 0.15 M NaCl, 0.05% sodium azide and 30% glycerol.
Analysis Note
Control
Human IFN-gamma stimulated HeLa cell lysates, IFN gamma stimulated human peripheral blood lymphocytes.
Routinely evaluated by Western Blot on untreated and IFNgamma treated (24 hrs) Hela lysates.

Western Blot Analysis:
1:500 dilution of this lot detected IDO on 10 ug of untreated and IFN gamma treated Hela lysates.
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Replaces: 04-1056
Legal Information
UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany